Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35072702.
- Also identified by DOI 10.1001/jamaneurol.2021.5109 and PMC identifier 8787678.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.
Medical subject headings
- COVID-19
- Multiple Sclerosis